Clinical Study
Triamcinolone and Bevacizumab as Adjunctive Therapies to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Table 2
Changes in the number of active new vessels (No. NV), best corrected visual acuity (BCVA), and central macular thickness (CMT) in the different groups before and after treatments, expressed as mean (SD).
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The Student’s t test was used to compare the changes in outcomes to the baseline for the three groups. BCVA, best-corrected visual acuity; CMT, central macular thickness; No. NV: number of new vessels; IVB: intravitreal bevacizumab; IVT: intravitreal triamcinolone; PRP: panretinal photocoagulation; SD: standard deviation. |